Codex Genetics Expands Precision Oncology Portfolio with Cxbladder Genomic Urine Tests
Strategic partnership with Pacific Edge offers Hong Kong clinicians a powerful tool for non-invasive bladder cancer detection and monitoring.
HONG KONG, Aug. 8, 2025 /PRNewswire/ -- Codex Genetics, one of the leading precision diagnostics companies in Hong Kong, today announced an exclusive collaboration with Pacific Edge, the developer of the Cxbladder suite of non-invasive genomic urine tests, to bring its advanced bladder cancer diagnostics to hospitals and clinics across Hong Kong.
Under this partnership, Codex Genetics will offer access to Cxbladder's full range of clinically validated tests—including Cxbladder Detect, Cxbladder Monitor, and Cxbladder Triage—designed to support urologists and oncologists in the risk stratification and surveillance of urothelial bladder cancer. These precision urine-based tests integrate genomic biomarker analysis with clinical algorithms to deliver actionable insights earlier in the patient care pathway.
Importantly, following a February 2025 update, Cxbladder Triage is included in the Microhematuria Guideline[1] issued by the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU). The amended Guideline incorporates language supporting the use of urine-based biomarkers to reduce reliance on cystoscopy and Cxbladder Triage is mentioned specifically, supported with "Grade A" evidence from a randomized controlled trial – the STRATA study[2].
"Our collaboration with Cxbladder reflects Codex's continued commitment as a leading diagnostics company in Hong Kong to advance precision medicine across Asia," said Dr. Aldrin Yim, co-founder of Codex Genetics. "Bladder cancer is one of the most expensive cancers to manage due to its high recurrence rate and need for lifelong monitoring. By offering a reliable non-invasive alternative that can reduce the need for cystoscopy, we aim to enhance clinical workflows, allowing clinicians to prioritize time and resources on those who need it the most. This improves the quality of care for patients in both public and private healthcare systems."
"We are excited to partner with Codex Genetics to expand access to Cxbladder in Hong Kong," said Dr. Peter Meintjes, CEO of Pacific Edge. "Codex's regional leadership in precision diagnostics makes them an ideal partner to deliver Cxbladder's value to clinicians and patients seeking reliable and less burdensome approaches to bladder cancer testing."
Bladder cancer is the ninth most common cancer worldwide, with high recurrence contributing to its significant clinical and economic burden. Cxbladder has been used in over 100,000 patients globally and is supported by more than 25 peer-reviewed clinical studies demonstrating high sensitivity and negative predictive value. Its adoption can reduce the need for unnecessary invasive procedures and optimize clinical decision-making.
Clinicians in Hong Kong interested in Cxbladder testing may contact Codex Genetics via www.codexgenetics.com for onboarding and access information.
[1] Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. doi: 10.1097/JU.0000000000004490. |
[2] Lotan et al. (2024). A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212 1-8 Jul 2024. |
Contact:
Whatsapp: (+852) 9837 1345
Phone: (+852) 3008 2560
Email: [email protected]
SOURCE Codex Genetics Limited
Share this article